These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 19846853)

  • 41. [Atypical hemolytic uremic syndrome].
    Fujimura Y
    Rinsho Ketsueki; 2013 Oct; 54(10):1897-906. PubMed ID: 24064841
    [No Abstract]   [Full Text] [Related]  

  • 42. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.
    Lehtinen MJ; Rops AL; Isenman DE; van der Vlag J; Jokiranta TS
    J Biol Chem; 2009 Jun; 284(23):15650-8. PubMed ID: 19351878
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome.
    Boels MG; Lee DH; van den Berg BM; Dane MJ; van der Vlag J; Rabelink TJ
    Eur J Intern Med; 2013 Sep; 24(6):503-9. PubMed ID: 23357408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent advances in the management of atypical hemolytic uremic syndrome.
    Cataland SR
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):537-9. PubMed ID: 23073053
    [No Abstract]   [Full Text] [Related]  

  • 45. A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: case report.
    Albertazzi V; Bonucchi D; De Amicis S; Americo C; Ghiandai G; Cappelli G
    Transplant Proc; 2010 May; 42(4):1352-4. PubMed ID: 20534299
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient.
    Chan MR; Thomas CP; Torrealba JR; Djamali A; Fernandez LA; Nishimura CJ; Smith RJ; Samaniego MD
    Am J Kidney Dis; 2009 Feb; 53(2):321-6. PubMed ID: 18805611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel use of intravenous immunoglobulin G in complement factor H missense mutation: a case report.
    Neidich AB; Neidich EM; Lee A; Nicoletta J; Rohrer RJ; Milner LS; Cooper JT
    Prog Transplant; 2013 Sep; 23(3):213-6. PubMed ID: 23996939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir.
    Olie KH; Goodship TH; Verlaak R; Florquin S; Groothoff JW; Strain L; Weening JJ; Davin JC
    Am J Kidney Dis; 2005 Jan; 45(1):e12-5. PubMed ID: 15696434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complement factor H and the hemolytic uremic syndrome.
    Atkinson JP; Goodship TH
    J Exp Med; 2007 Jun; 204(6):1245-8. PubMed ID: 17548524
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.
    Sellier-Leclerc AL; Fremeaux-Bacchi V; Dragon-Durey MA; Macher MA; Niaudet P; Guest G; Boudailliez B; Bouissou F; Deschenes G; Gie S; Tsimaratos M; Fischbach M; Morin D; Nivet H; Alberti C; Loirat C;
    J Am Soc Nephrol; 2007 Aug; 18(8):2392-400. PubMed ID: 17599974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.
    Moore I; Strain L; Pappworth I; Kavanagh D; Barlow PN; Herbert AP; Schmidt CQ; Staniforth SJ; Holmes LV; Ward R; Morgan L; Goodship TH; Marchbank KJ
    Blood; 2010 Jan; 115(2):379-87. PubMed ID: 19861685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Atypical haemolytic uraemic syndrome.
    Kavanagh D; Goodship TH; Richards A
    Br Med Bull; 2006; 77-78():5-22. PubMed ID: 16968692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity.
    Blom AM; Bergström F; Edey M; Diaz-Torres M; Kavanagh D; Lampe A; Goodship JA; Strain L; Moghal N; McHugh M; Inward C; Tomson C; Frémeaux-Bacchi V; Villoutreix BO; Goodship TH
    J Immunol; 2008 May; 180(9):6385-91. PubMed ID: 18424762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complement factor H and the haemolytic uraemic syndrome.
    Taylor CM
    Lancet; 2001 Oct; 358(9289):1200-2. PubMed ID: 11675053
    [No Abstract]   [Full Text] [Related]  

  • 55. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.
    Licht C; Weyersberg A; Heinen S; Stapenhorst L; Devenge J; Beck B; Waldherr R; Kirschfink M; Zipfel PF; Hoppe B
    Am J Kidney Dis; 2005 Feb; 45(2):415-21. PubMed ID: 15685522
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
    Kavanagh D; Burgess R; Spitzer D; Richards A; Diaz-Torres ML; Goodship JA; Hourcade DE; Atkinson JP; Goodship TH
    Mol Immunol; 2007 May; 44(12):3162-7. PubMed ID: 17368771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.
    Józsi M; Strobel S; Dahse HM; Liu WS; Hoyer PF; Oppermann M; Skerka C; Zipfel PF
    Blood; 2007 Sep; 110(5):1516-8. PubMed ID: 17495132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. C3 Glomerulonephritis With Multiple Mutations in Complement Factor H.
    Dalili N; Behnam B; Vali F; Parvin M; Torbati P; Rasaii N; Samadian F; Ahmadpoor P
    Iran J Kidney Dis; 2018 Nov; 12(6):376-381. PubMed ID: 30595568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
    Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option?
    Hirt-Minkowski P; Schaub S; Mayr M; Schifferli JA; Dickenmann M; Frémeaux-Bacchi V; Steiger J
    Nephrol Dial Transplant; 2009 Nov; 24(11):3548-51. PubMed ID: 19633317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.